Previously, we reported the discovery of a series of N-hydroxycinnamamide-based HDAC inhibitors, among which compound 11y exhibited high HDAC1/3 selectivity. In this current study, structural derivatization of 11y led to a new series of benzamide based HDAC inhibitors. Most of the compounds exhibited high HDACs inhibitory potency. Compound 11a (with 4-methoxybenzoyl as N-substituent in the cap and 4-(aminomethyl) benzoyl as the linker group) exhibited selectivity against HDAC1 to some extent, and showed potent antiproliferative activity against several tumor cell lines. In vivo studies revealed that compound 11a displayed potent oral antitumor activity in both hematological tumor cell U937 xenograft model and solid tumor cell HCT116 xenograft model with no obvious toxicity. Further modification of benzamide 3, 11a and 19 afforded new thienyl and phenyl compounds (50a, 50b, 63a, 63b and 63c) with dramatic HDAC1 and HDAC2 dual selectivity, and the fluorine containing compound 56, with moderate HDAC3 selectivity.
Introduction
It is widely considered that the initiation and progression of cancer are associated with genetic abnormalities, as well as epigenetic alterations that do not change the nucleotide sequence of DNA [1] . Histone deacetylases (HDACs) are one of the most studied epigenetic modulators, modifying the acetylation status of chromatin histones and non-histone proteins [2] . In detail, HDACs remove acetyl groups from lysine residues, resulting in a "closed" chromatin configuration, which blocks the access of the transcription machinery to DNA, and suppresses gene expression including tumor suppressor genes [3] .
Currently a total of 18 HDACs have been identified in humans, which can be divided into 4 classes according to their homology. Class I includes HDACs 1, 2, 3, and 8, and they are homologous to yeast Rpd3; class IIa (HDACs 4, 5, 7 and 9) and class IIb (HDAC6 and 10) are structurally related to yeast Hda1; Class IV has only one member, HDAC11. These HDAC isoforms are all Zn 2þ -dependent enzymes, which bear a highly conserved catalytic site. The class III HDACs (comprising SIRT 1-7) are related to the yeast protein Sir2 and their activities are depended on NAD þ concentration [4, 5] . The exact physiological role of these HDAC subtypes in cells is far from being completely elucidated, however, the division of labor among them has been studied using knockout and transgenic mice and RNAi techniques, in which, class I and class II are the most well studied [6, 7] . The knockout of HDAC1 in mice caused cell proliferation defects and developmental retardation, and this unique function cannot be compensated by HDAC2 and HDAC3 [8, 9] . HDAC2 is involved in cardiac morphogenesis until the perinatal period of mice [10] . HDAC3 has been reported to function in proliferative mitosis and the regulation of INF expression [11] . In normal human tissues, HDAC8 is associated with the regulation of the contractile capacity [12] . Unlike class I HDACs, Class IIa HDACs (HDAC4, 5, 7 and 9) display tissue-specific expression and are involved in a variety of signal transduction pathways [13] . The wellknown class IIb HDAC6 controls the status of tubulin and hsp90 acetylation [14] . All these indicates each HDAC enzyme has its unique function in normal cells, therefore, most pan-HDAC inhibitors (HDACIs), which inhibit a broad spectrum of HDACs, exhibited significant toxicity. For example, panobinostat (LBH589) caused serious thrombocytopenia, atrial fibrillation, eye swelling, neutropenia, and anemia [15] . Thus, increasing efforts are being directed toward developing selective HDACIs for a single class or a single isoform, which are likely to have fewer adverse reactions and a better tolerance. A few Class I selective HDACIs such as MS-275 and MGCD0103 (HDAC1, 2, and 3-selective) are currently in various stages of clinical trial for cancer therapeutics [16] , and Chidamide recently has been approved by China food and drug administration (CFDA).
In our previous study, we designed and synthesized N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral anti-leukemia activity [17] . Efforts to improve the selectivity of the dually reported the discovery of a new series of benzamides based HDACIs. The structure-activity relationship (SAR) studies, isotype-selectivity, and anticancer activities of benzamide HDACIs were particularly discussed. One representative compound 11a exhibited selectivity against HDAC1, and showed potent antiproliferative activity against solid and hematological tumor cell lines both in vitro and in vivo. Further modified thienyl and phenyl compounds all exhibited dramatic HDAC1/2 dual selectivity.
Chemistry
The synthesis of compound 3 was described in Scheme 1. The synthesis of the starting material 1 was described in our previous study [18] . Deprotection of methyl group of 1 in the presence of KOH aqueous solution yielded 2, which was then coupled with ophenylenediamine in anhydrous THF to yield the final product 3.
The synthesis of compounds 11a-11g was described in Scheme 2. Methyl ester protection of 5 gave rise to 6, which was then reacted with Boc-protected L-Trp by TBTU-mediated amide formation to afford 7. N-deprotection of 7 followed by condensation with different carboxylic acids gave 9a-9g, which were deprotected in the presence of KOH aqueous solution to obtained 10a-10h. 10a-10h were then subjected to hydrolysis reaction and amide formation reaction as 2 in Scheme 1 to yield the final products 11a-11g, respectively.
Scheme 3 was similar to that of Scheme 2. 12 was reacted with 4-methoxybenzoic acid via condensation to get 13. 15 was subjected to methyl ester protection to afford 16. 14, the hydrolysis products of 13, was then connected with 16 to get 17 which was subjected to methyl deprotection and amide formation reaction as 3 in Scheme 1 to yield 19.
Compound 20 of Scheme 4 was reported as an intermediate in our previous study [17] , and it was transformed into compound 22 by the same reaction in Scheme 1.
Methyl ester protection of 24a and 24b gave 25a and 25b, which were connected with 23 through Mitsunobu reaction to give 26a and 26b (Scheme 5). Intermediate 27a and 27b, the N-deprotected product of 26a and 26b, were reacted with 4-methoxybenzoic acid to afford 28a and 28b, which were further subjected to methyl deprotection and condensation to yield the final products 30a and 30b, respectively.
Compound 37 was synthesized following the procedures described in Scheme 6. Condensation between intermediate 14 and N,O-dimethylhydroxylamine hydrochloride yielded 31, which was subsequently converted to aldehyde 32 by LiAlH 4 at À40 C. 32 was reacted with 6 in the presence of NaBH 3 CN to afford 33. Bocprotection, methyl deprotection, amide formation reaction and Ndeprotection of 33 yielded the target product 37.
The reaction for 43a and 43b was described in Scheme 7. Bocprotection of 38 gave 39, which was coupled with thiophene-2-boronic acid or phenylboronic acid using Suzuki reaction in the presence of Pd(OAc) 2 to afford 40a or 40b. Catalytic hydrogenation of 40a and 40b gave 41a and 41b, which were subjected to amide formation reaction and N-deprotection to obtain 43a and 43b, respectively.
Emmanuel H. Demont et al. described the synthesis of 46 [19] , briefly, double Boc-protection of 44 gave 45, then one Bocprotecting group was removed in the presence of trifluoroacetic acid to afford mono-Boc protected product 46. Reduction of 46 gave 47, which was subjected to a similar reaction of 41 in Scheme 7 to yield 49 (Scheme 8).
6 and 50 were treated with trifluoroacetic anhydride to yield trifluoroacetyl protected 51a and 51b, respectively. 51a and 51b were converted to acyl chloride 52a and 52b. 52a was subsequently reacted with 41a to afford product 53a, while 52b was reacted with 41a and 41b to achieve 53b and 53c, respectively (Scheme 9). Trifluoroacetyl deprotection of 53a-53c gave 54a-54c, which were subjected to a similar reaction of 41 in Scheme 7 to yield 56a-56c. The synthesis of 60a and 60b in Scheme 10 was similar to the reaction of 52a converting to 56a, and this route would not be described in this section.
Results and discussion
Our previous study described the discovery of several Nhydroxycinnamamide-based HDACIs with HDAC 1/3 inhibitory activity [17] . However, due to its strong chelating ability with zinc ions, hydroxamates unavoidably exhibited inhibitory activity against other HDAC subtypes including HDAC 2, 8, 6 and so on. Therefore, we attempted to replace hydroxamic acid with other zinc-binding groups to obtain HDACIs with better isoform selectivity. To the best of our knowledge, most of the sub-class I selective inhibitors currently in research are benzamide HDACIs, such as MS-275, MGCD0103, CI994 and RG2833. Therefore, we kept the cap group (or the cap and the linker groups) of the representative HDAC1/3 selective inhibitor 11y unchanged, and introduced the linker and zinc binding group (ZBG) of aforementioned sub-class I selective inhibitors to obtain a novel series of hybrid compounds, 3, 11a, 19, 22, 30a, 30b, 37 (Fig. 1) . In detail, 3 was designed by combining cap group of 11y with linker and ZBG group of CI994. Using the same strategy, 11a and 19 were derived by combining the cap group of 11y with the linker and the ZBG group of MS275 and RG2833, respectively. Keeping both the cap group and the linker of 11y unchanged while replacing hydroxamate with the benzamide as ZBG led to 22. Moreover, 30a, 30b and 37 were achieved by further modification of the linker group of 22 and 11a (Fig. 1) .
HDAC class I whole cell assay and antiproliferative assay based on the human leukemia cell line HL60 were conducted to efficiently screen the newly designed compounds (Table 1) . Benzamides 3, 11a, 19, 22, 30a, 30b and 37 with different linker groups exhibited diverse class I HDAC inhibitory activities. To be specific, 3, 11a and 30a, bearing linker structure of N-(p-tolyl)acetamide, N-(4-methylbenzyl)acetamide and 1-ethoxy-4-methylbenzene, respectively, displayed submicromolar IC 50 values (0.67e0.85 mM), comparable with that of MS275 (0.62 mM). 19 with N-hexylacetamide, 22 with (E)-1-ethoxy-4-(prop-1-en-1-yl)benzene and 37 with N-(4-methylbenzyl)ethanamine as linker group showed low micromolar IC 50 values (1.23e2.95 mM), while 30b having one carbon longer than 30a in the linker chain length displayed no inhibitory activity up to 10 mM. These results indicated that changes in the linkers had obvious effects on the inhibitory activities of benzamide based HDACs inhibitors. The antiproliferative activity of all the compounds was consistent with their cellular enzymatic activity, 30b showed no anti-proliferative activity at the concentration up to 20 mM. The other benzamides displayed low micromolar IC 50 values, among which, the most potent compounds 3, 11a and 30a also exhibited comparable antiproliferative activities to MS275.
Due to its promising enzymatic and antiproliferative activity, further structural modification was focused on the cap of 11a to find more potent derivatives. Analogs 11b-11g were designed and synthesized by replacing the 4-methoxybenzoyl of 11a with various para substituted benzoic acids or heterocyclic rings. Among these analogs, 11f (with 2-thiophenecarboxyl), 11g (with 2-furancarboxyl), and their parent compound 11a displayed higher enzymatic inhibitory and antiproliferative activity than the other compounds (Table 2) .
In order to explore the HDAC isoform selective profile, compounds 3, 11a, 19, 22, 30a, 30b, and 37, with different linkers, were evaluated in enzyme inhibitory assays against HDAC1, HDAC2 and HDAC3. Results presented in Table 3 revealed that compounds 3, 11a and 30a exhibited moderate HDAC1 selectivity; 19 displayed moderate HDAC1/3 dual selectivity; 37 showed some preference to HDAC1/2; 30b was not active in cellular assays and also showed no inhibition against HDAC1/2/3 up to 20 mM; 22 showed almost no selectivity among HDAC1/2/3. Considering its moderate HDAC1 selectivity (Table 3 ) and promising cellular enzyme activity and antiproliferative activity (Table 1) , 11a was chosen for further evaluation.
The MTT assay results in Table 4 indicated that 11a exhibited similar in vitro antiproliferative activities against several hematological and solid tumor cell lines to MS275. 11a and MS275 displayed low micromolar or submicromolar IC 50 values against HEL, K562, U937, U266 and HCT116 cell lines, while showed poor antiproliferative activity against ES-2.
Encouraged by its promising in vitro activity, compound 11a was further progressed to in vivo experiments. Firstly, we established a hematological tumor xenograft model, using MS275 as the positive control, to investigate if 11a was active in vivo. 5 Â 10 6 U937 cells were subcutaneously implanted in the right flanks of male nude mice (BALB/c-nu). Once tumor size reached about 100 mm 3 , mice were randomized into seven per group and were treated with compound 11a (100 mg/kg/day) or MS275 (50 mg/kg/day) by oral gavage for 13 days. Tumor growth inhibition (TGI) and relative increment ratio (T/C) were calculated at the end of experiment to reveal the antitumor effects via tumor weight and tumor volume, respectively. Meanwhile, tumor volume and mice body weight were also measured during the treatments (Fig. 2 , Table 5 ). Although compound 11a displayed potent in vivo oral antitumor activity with TGI value of 51% and T/C value of 49%, it was a little less potent than the positive control MS275 (TGI ¼ 60%, T/C ¼ 33%). However, we could see from Fig. 2d and Table 5 that during treatment, the mice group administrated with MS275 demonstrated obvious body weight loss compared with the control group, which indicated that MS275 had obvious toxicity in the dose of 50 mg/kg/ day. This toxicity didn't appear in the mice treated with 11a in the dose of 100 mg/kg/day. In fact, at the beginning of the in vivo study, mice were treated with MS275 at the same dosage as 11a (100 mg/ kg/day). Three days later, serious body weight loss was observed unexpectedly, and after six days, two of the six mice died. Therefore, we had to setup a new in vivo experiment and decreased the dose of MS275 to 50 mg/kg/day. In conclusion, compound 11a exhibited potent in vivo oral antitumor activity in the U937 xenograft model without obvious side effects compared with MS275.
Another subcutaneous colon cancer cell HCT116 xenograft model was also established to test if 11a was effective against solid tumor in vivo. Mice were treated with 11a (100 mg/kg), SAHA (100 mg/kg) or MS275 (50 mg/kg) by oral gavage for 16 days. Results in Fig. 3 and Table 6 showed that significant tumor growth delays were observed relative to the untreated group for all tested compounds. Compound 11a (TGI ¼ 49%, T/C ¼ 59%) was much more effective than SAHA (TGI ¼ 32%, T/C ¼ 74%), while was less potent than positive control MS275 (TGI ¼ 62%, T/C ¼ 47%). Again, compared with the control group, serious body weight loss was observed in MS275 group but not in 11a group and SAHA group (Table 6 ). Taken together, our benzamide 11a was orally active not only in the hematological tumor cell U937 xenograft model but also in the solid tumor HCT116 xenograft model. Though less potent, 11a possessed much better safety profiles than the clinical compound MS275.
Previous reports demonstrated that a 14 Å internal cavity immediately below the zinc binding group could be used to design HDAC1/2 selective HDACs inhibitors effectively [20] . Another report showed the introduction of fluorine in the para position of acid amide could decrease the activity against HDAC1 to afford a HDAC3 selective inhibitor [21] . Therefore, compounds 43a, 43b, 49, 56a-56c, 60a and 60b were designed based on 3, 11a or 19, and these new compounds were expected to display different selective profiles (Fig. 4) .
All of the newly designed compounds were evaluated in enzyme inhibitory assays against HDAC1, HDAC2 and HDAC3 along with 19, 3 and 11a (Table 7) . Results revealed that regardless of the linker, para aromatic substituent of compounds 19, 3 and 11a could obviously decrease their inhibitory activity against HDAC3, which was consistant with previous reports [20] . Among compounds 49, 60a and 60b with fluorine in the para position of acid amide, only 49 displayed moderate HDAC3 selectivity, which indicated the para fluorine plus the appropriate linker, such as the linear aliphatic liner in 49, co-determined the selective profile of HDAC inhibitor. To further ascertain the selectivity of our compounds across the broader family of HDAC isoforms, we next profiled the representative 43a with para aromatic substituent, 49 with fluorine against HDAC8 (class I), HDAC4 (class IIa), and HDAC6 (class IIb).
43a and 49 displayed almost no activity (>100 mM) against HDAC8, HDAC4 and HDAC6 (see Table 8 ).
Several HDAC1/2 selective compounds 43a, 43b, 56b and 56c were tested in antiproliferative assays (Table 9) . Results showed all these HDAC1/2 selective compounds displayed much weaker antiproliferative activities than their parent compounds 19 and 11a. In order to explain this result, we conducted western blot assay to determine the levels of acetylated histone H3, acetylated histone H4 and several apoptosis-related proteins including procaspase-3, cleaved caspase-3 and cleaved PARP (Poly ADP ribose polymerase) in tumor cells treated with 11a, 56c and positive control MS275, respectively. Result in Fig. 5 displayed that compound 11a could markedly increase the level of acetylated histone H3 and acetylated histone H4, which was much superior to 56c at the same concentration. In addition, compound 11a and MS275 dramatically reduced the level of procaspase-3 and increased the level of cleaved caspased-3 and cleaved PARP, which indicated the induction of apoptosis, however, the levels of procaspase-3, cleaved caspased-3 and cleaved PARP could be hardly affected by 56c. The above western blot results of 11a, 56c and MS275 were consistent with their antiproliferative activities.
Conclusion
A new series of benzamide-based HDACIs were designed and synthesized, and their structure-activity relationship (SAR), isotype-selectivity, and anticancer activities were described. Most of the compounds exhibited high HDAC inhibitory potency. Any changes in the linker fragment and the N-substituent in the cap all had influence in HDAC inhibitory activity and antiproliferative potency of benzamide HDACIs. 11a, with 4-methoxybenzoyl as Nsubstituent in the cap and 4-(aminomethyl) benzoyl as linker group, exhibited the best activity and exhibited some HDAC1 selective profile. In addition, 11a also showed potent antiproliferative activity against multiple solid or hematological tumor cell lines. In vivo studies revealed that compound 11a displayed potent oral antitumor activity in the U937 and HCT116 xenograft models. Although it was a little less potent than the positive control MS275, 11a did have a much better tolerance with almost no toxicity in mice.
The newly designed thienyl and phenyl compounds (43a, 43b, 56a, 56b and 56c) based on 19, 3 and 11a exhibited dramatic HDAC1/2 dual selectivity. One representative compound 56c showed low nanomolar IC 50 values against HDAC1 (58.4 nM), submicromolar IC 50 values against HDAC2 (311 nM) and micromolar IC 50 values against HDAC3 (30850 nM). Compounds 49, 60a and 60b with fluorine in the para position of acid amide were also synthesized, among which, 49 displayed moderate HDAC3 selectivity. Disappointingly, our HDAC1/2 selective compounds exhibited poor in vitro antiproliferative activity, which was consistent with the western blot results that 56c displayed much less effects on acetylated histone H3, acetylated histone H4, procaspase-3, cleaved caspase-3 and cleaved PRAP than its parent compound 11a. Considering that it was reported that thienyl based HDAC1/2 inhibitors exhibited better antiproliferative activity than their parent HDAC1/2/3 inhibitors [20] , we supposed that the poor cellular potency of 56c should be due to its poor transmembrane permeability rather than its lack of HDAC3 inhibition. Actually, our preliminary results showed that the intracellular fluid concentration of 56c was more than 10 times lower than 11a (data not shown). Besides, we also detected the solubility of 56c by testing lip-water partition coefficient (LogP), however, we could hardly detect 56c in water phase (compound concentration in n-octyl alcohol was 5 mM) due to its poor water solubility, which could be partially responsible for its poor transmembrane permeability. Further study focused on the improvement of compounds' water solubility and transmembrane permeability is underway in our lab.
Experiment section
Materials and Methods. High-resolution mass spectrometry was performed by Shandong Analysis and Test Center in Ji'nan, China. ESI-MS spectra were recorded on an API 4000 spectrometer. The [MþH] þ data of HRMS or ESI-MS consisted with the calculated molecular mass of compounds. 1 H NMR and 13 C NMR spectra were obtained on a Bruker DRX spectrometer at 400 MHz with TMS as an internal standard, d in parts per million and J in hertz.
1 H NMR and 13 C NMR peaks consisted with the structures of compounds. All reactions were monitored by TLC using 0.25 mm silica gel plates (60 GF-254). UV light and ferric chloride were used to visualize the spots. Silica gel was used for column chromatography purification. Flash chromatography was accomplished using the automated CombiFlash Rf system from Teledyne ISCO and was done using silica gel of 200e300 mesh. Melting points were determined on an electrothermal melting point apparatus. All tested compounds are >95% pure by HPLC analysis, performed on an Agilent 1100 HPLC instrument using an ODS HYPERSIL column (5 mm, 4.6 mm Â 250 mm).
3.1.1. General procedure for the preparation of 6 and 16 3.1.1.1. Methyl 4-(aminomethyl)benzoate hydrochloride (6). Compound 5 (1.5 g, 10 mmol) was dissolved in 200 mL MeOH, then acetyl chloride (2.4 g, 30 mmol) was added dropwise at 0 C; the mixed solution was refluxed at 75 C for 5 h. The solvent was evaporated under vacuum, the product was washed by diethyl ether to give compound 6, a white solid powder (1.7 g, 93%).
3.1.1.2. Methyl 6-aminohexanoate hydrochloride (16) . Using the synthetic method for 5, compound 15 gave 16 as a white solid, 94% yield.
3.1.2. General procedure for the preparation of 25a and 25b 3.1.2.1. Methyl 4-hydroxybenzoate (25a). 24a (2.76 g, 20 mmol) was dissolved in 100 mL MeOH, then acetyl chloride (4.7 g, 60 mmol) was added dropwise at 0 C; the mixed solution was refluxed at 75 C for 5 h. The solvent was evaporated under vacuum, the product dissolved with EtOAc, washed by saturated NaHCO 3 solution (2 Â 100 mL), 1 M aqueous citric acid (2 Â 100 mL) and brine (2 Â 100 mL), dried over MgSO 4 overnight and evaporated under vacuum to obtained product compound 25a, a white solid (7.98 g, 
Methyl 2-(4-hydroxyphenyl)acetate (25b).
Using the synthetic method for 25a, compound 24b gave 25b as a white solid, 81% yield.
3.1.3. General procedure for the preparation of 26a and 26b
Compound 23 (2.90 g, 10 mmol), 25a (1.82 g, 12 mmol), and PPh 3 (3.95 g, 15 mmol) were dissolved in anhydrous THF, then DEAD (2.61 g, 15 mmol) was added dropwise at 0 C, the mixture was stirred for 4 h, then THF was evaporated. The crude material was purified via flash chromatography to afford the compound 26a, a white solid (2.52 g, 60%). ESI-MS m/z: 
Methyl (S)-4-((2-(4-(dimethylamino)benzamido)-3-(1H-indol-3yl)propanamido) methyl)benzoate (9b).
Using the synthetic method for 7, compound 4-(dimethylamino)benzoic acid and 8 gave 9b as a white solid, 55% yield.
Methyl (S)-4-((3-(1H-indol-3-yl)-2-(4-(trifluoromethyl)benzamido)propanamido) methyl)benzoate (9c).
Using the synthetic method for 7, compound 4-(trifluoromethyl)benzoic acid and 8 gave 9c as a white solid, 52% yield. ESI-MS m/z: 524.5 [MþH] þ . 3.1.4.5. Methyl (S)-4-((3-(1H-indol-3-yl)-2-(picolinamido)propanamido)methyl)benzoate (9d). Using the synthetic method for 7, compound picolinic acid and 8 gave 9d as a white solid, 58% yield.
Using the synthetic method for 7, compound pyrazine-2-carboxylic acid and 8 gave 9e as a white solid, 54% yield.
Using the synthetic method for 7, compound thiophene-2-carboxylic acid and 8 gave 9f as a white solid, 54% yield. (9 g). Using the synthetic method for 7, compound furan-2-carboxylic acid and 8 gave 9g as a white solid, 56% yield.
. Using the synthetic method for 7, compound 4-methoxybenzoic acid and 12 gave 13 as a white solid, 52% yield. (17) . Using the synthetic method for 7, compound 14 and 16 gave 17 as a white solid, 52% yield.
3.1.4.11. Methyl (S)-4-(3-(1H-indol-3-yl)-2-(4-methoxybenzamido) propoxy)benzoate (28a). Using the synthetic method for 7, compound 4-methoxybenzoic acid and 27a gave 28a as a white solid, 52% yield. 3.1.4.14. Tert-butyl (S)-(2-(3-(1H-indol-3-yl)-2-(4 methoxybenzamido)propanamido)ethyl) carbamate (39a). Using the synthetic method for 7, compound 14 and 38a gave 39a as a white solid, 70% yield. 3 .1. 4 .15 . Te r t -b u t y l ( S ) -( 3 -( 3 -( 1 H -i n d o l -3 -y l ) -2 -( 4 -methoxybenzamido)propanamido)propyl) carbamate (39b). Using the synthetic method for 7, compound 14 and 38b gave 39b as a white solid, 65% yield. 3.1.5.2. Methyl (S)-4-(2-amino-3-(1H-indol-3-yl)propoxy)benzoate hydrochloride (27a). Using the synthetic method for 7, compound 26a gave 27a as a white solid, 78% yield.
3.1.5.3. Methyl (S)-2-(4-(2-amino-3-(1H-indol-3-yl)propoxy)phenyl) acetate (27b). Using the synthetic method for 7, compound 26b gave 27b as a white solid, 82% yield.
Using the synthetic method for 7, compound 36 gave 37 as a white solid, 78% yield. Mp: 180e182 C. 
. Methyl(S)-4-(((3-(1H-indol-3-yl)-2-(4-methoxybenzamido)
propyl)(tert-butoxy carbonyl)amino)methyl)benzoate (34). At room temperature, to a solution of 33 (1.41 g, 3 mmol) in anhydrous CH 2 Cl 2 (20 mL), was added Et 3 N (0.91 g, 9 mmol) followed by (Boc) 2 O (0.78 g, 3.6 mmol). After stirring the mixture at room temperature for 8 h, the solution was washed with 1 M aqueous citric acid (3 Â 10 mL) and brine (3 Â 10 mL), dried over MgSO 4 , and evaporated under vacuum to yield the crude product compound 34 (1.54 g, 90% yield) as a white solid. This product was used for the following reaction without further purification. ESI-MS m/z: 572. 
. (S)-4-(3-(1H-indol-3-yl)-2-(4-methoxybenzamido)propanamido)benzoic acid (2).
Compound 1 (0.56 g, 1.2 mmol) was dissolved in 5 mL CH 3 OH, then 2 mL 3 M KOH aqueous solution was added. The mixture was refluxed at 85 C for 2 h. After the reaction completed, it was evaporated under vacuum. The residue was acidified with 1 N HCl to pH 3-4, then filtered. The precipitate was 2, a white solid, 85% yield. 
(S)-4-((3-(1H-indol-3-yl)-2-(4-methoxybenzamido)propanamido)methyl)benzoic acid (10a

(S)-4-((2-(4-(dimethylamino)benzamido)-3-(1H-indol-3-yl)
propanamido)methyl) benzoic acid (10b). Using the synthetic method for 2, compound 9b gave 10b as a white solid, 87% yield.
(S)-4-((3-(1H-indol-3-yl)-2-(4-(trifluoromethyl)benzamido) propanamido)methyl) benzoic acid (10c).
Using the synthetic method for 2, compound 9c gave 10c as a white solid, 80% yield.
(S)-4-((3-(1H-indol-3-yl)-2-(picolinamido)propanamido) methyl)benzoic acid (10d).
Using the synthetic method for 2, compound 9d gave 10d as a white solid, 85% yield. 1 a Assays were performed in replicate (n ! 2); The SD values are < 20% of the mean. a Assays were performed in replicate (n ! 2); The SD values are < 20% of the mean. a Assays were performed in replicate (n ! 2); The SD values are < 20% of the mean. 2 Cl 2 (300 mL), Et 3 N (15.17 g, 150 mmol) was added followed by (Boc) 2 O (2.18 g, 100 mmol) and DMAP (4-dimethylaminopyridine) (0.06 g, 0.5 mmol). After stirring the mixture at room temperature for 2 h, the solution was washed with 1 M aqueous citric acid (3 Â 100 mL) and brine (3 Â 100 mL), dried over MgSO 4 , and evaporated under vacuum to get the crude product. The crude product was recrystallized by EtOAc and petroleum ether to achieve a white pure solid (8.71 g, 55%). 1 3.1.11. General procedure for the preparation of 46 3.1.11.1. Tert-butyl (5-fluoro-2-nitrophenyl)carbamate (46). A solution of 45 (3.57 g, 10 mmol) in CH 2 Cl 2 (100 mL) at room temperature was treated with TFA (1.14 g, 10 mmol) drop wise, and the resulting mixture was stirred at this temperature for 80 min before being treated with a saturated NaHCO 3 aqueous solution. The layers were separated, and the organic phase was washed with a saturated NaHCO 3 aqueous solution, dried over Na 2 SO 4 concentrated in vacuo to give 46 (0.23 g, 90%) as a yellow solid, which was used in the next step without further purification. ESI-MS m/z:
(S)-4-((3-(1H-indol-3-yl)-2-(pyrazine-2-carboxamido)propanamido)methyl) benzoic acid (10e
(S)-4-((3-(1H-indol-3-yl)-2-(thiophene-2-carboxamido) propanamido) methyl)benzoic acid (10f
3.1.12. General procedure for the preparation of 40a and 40b 3.1.12.1. Tert-butyl (2-nitro-4-(thiophen-2-yl)phenyl)carbamate (40a). To a solution of compound 39 (6.34 g, 20 mmol), thiophene-2-boronic acid (3.07 g, 24 mmol), PPh 3 (0.11 g, 0.4 mmol), Pd(OAc) 2 (0.04 g, 0.2 mmol) in 20 mL DMSO Na 2 CO 3 (4.24 g, 40 mmol) was added dissolving in 15 mL of water under N 2 atmosphere. The N 2 protected reaction mixture was heated at 100 C for 5 h, after the reaction finished, the mixture was poured on 200 mL water and extracted by EtOAc. The organic phase was washed with saturated 1 M HCl (2 Â 30 mL), NaHCO 3 (2 Â 30 mL) and brine (2 Â 30 mL), dried over Na 2 SO 4 overnight, and the solvent was evaporated under vacuum. The crude material was purified via flash chromatography to afford the compound 40a (3.71 g, 58%) . 1 3.1.13. General procedure for the preparation of 41a, 41b and 47 3.1.13.1. Tert-butyl (2-amino-4-(thiophen-2-yl)phenyl)carbamate (41a). To a solution of 40a (3.43 g, 10 mmol) in CH 3 OH (200 mL), was added dry palladium-carbon (0.34 g), the mixture was stirred under a hydrogen atmosphere overnight. The palladium-carbon was filtered off over celite, after evaporating the solvent, the residue was dried under vacuum to give 41a (2.46 g, 85%) , a white solid. 3.1.14. General procedure for the preparation of 51a and 51b 3.1.14.1. 4-(2,2,2-trifluoroacetamido)benzoic acid (51a). 50 (2.74 g, 20 mmol) was dissolved in 10 mL TFA slowly at 0 C, the solution was stirred at room temperature for 2 h. After the reaction finished, the mixture was quenched by adding 100 mL ice water and filtered, the residue was dried under infrared drying oven to afford 51a (4.43 g, 95%).
4-((2,2,2-trifluoroacetamido)methyl)benzoic acid (51b).
Using the synthetic method for 51a, compound 6 gave 51b as a white solid, 98% yield. mp:214-215 C, 1 HNMR (400 MHz DMSO-
3.1.15. General procedure for the preparation of 53a-53c, 57a and 57b 3 .1.15 .1. Te r t -b u t y l ( 4 -( t h i o p h e n -2 -y l ) -2 -( 4 -( 2 , 2 , 2 -trifluoroacetamido)benzamido)phenyl) carbamate (53a). Compound 51a (1.16 g, 5 mmol) was dissolved in 15 mL SOCl 2 , the mixed solution was refluxed at 80 C for 5 h. The solvent was evaporated under vacuum, the product (52a) was dissolved with anhydrous CH 2 Cl 2 and was dropped in the CH 2 Cl 2 solution of 41a (1.45 g, 5 mmol) at 0 C followed by Et 3 N (0.51 g, 5 mmol). The mixture reacted at room temperature overnight, the solution was washed with 1 N HCl (2 Â 30 mL), saturated NaHCO 3 (2 Â 30 mL) and brine (2 Â 30 mL), dried over Na 2 SO 4 overnight, and the solvent was evaporated under vacuum. The crude product was recrystallized by EtOAc and petroleum ether to achieve a white pure solid (1.57 g, 62%). 4-((2,2,2-trifluoroacetamido) methyl)benzamido)-[1,1'-biphenyl]-4-yl)carbamate (53c). Using the synthetic method for 53a, compound 51b and 41b gave 53c as a white solid, 58% yield. ESI-MS m/z: 514.5 [MþH] þ .
3.1.15.4. Tert-butyl (5-fluoro-2-(4-(2,2,2-trifluoroacetamido)benzamido)phenyl)carbamate (57a). Using the synthetic method for 53a, compound 52a and 47 gave 57a as a white solid, 56% yield. 1 3.1.15.5. Tert-butyl(5-fluoro-2-(4-((2,2,2-trifluoroacetamido)methyl) benzamido) phenyl)carbamate (57b). Using the synthetic method for 53a, compound 52b and 47 gave 57b as a white solid, 48% yield.
3.1.16. General procedure of compound 54a-54c, 58a and 58b 3.1.16.1. Tert-butyl (2-(4-aminobenzamido)-4-(thiophen-2-yl) phenyl)carbamate (54a). To a solution of 53a (1.51 g, 3 mmol) in the mixture of 10 mL CH 3 OH and 10 mL H 2 O, K 2 CO 3 (1.24 g, 9 mmol) was added. The mixture was then stirred at room temperature overnight, and the CH 3 OH was evaporated under vacuum. The residue was extracted by EtOAc. The organic phase was washed with brine (2 Â 30 mL), dried over Na 2 SO 4 overnight, and the solvent was evaporated under vacuum to afford 54a (0.98 g, 80%). 
Tert-butyl (2-(4-(aminomethyl)benzamido)-4-(thiophen-2-yl)phenyl)carbamate (54b).
Using the synthetic method for 54a, compound 53b gave 54b as a white solid, 79% yield.
Using the synthetic method for 54a, compound 53c gave 54c as a white solid, 83% yield. [MþH] þ 600.2217, found 600.2220. þ .
HDAC class I cellular activity
The cellular HDAC assay was based on such assay described on patent WO20080952A1 with minor modifications. Briefly, human prostate cancer cell line HL60 were seeded into a 96-well tissue culture plates (Corning, Germany) at a density of 1.2 Â 10 4 cells/ well and allowed to grow for 24 h. Then cells were treated with increasing concentrations of test compounds for 3 h. The reaction was started by adding substrate Boc-Ac-Lys-AMC. 3 h later under cell culture conditions, stop solution (50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl 2 , 1% NP-40, 2.0 mg/mL trypsin, 10 mM TSA) was added and the mixture was incubated for another 3 h. Fluorescence intensity was measured using a microplate reader at excitation and emission wavelengths of 360 and 470 nm, respectively.
In vitro HDACs inhibition fluorescence assay
In vitro HDACs inhibition assays were conducted as previously described. 17 In brief, 10 mL of enzyme solution was mixed with different concentrations of tested compound (50 mL). The mixture was incubated at 37 C for 10 min, then 40 mL fluorogenic substrate (Boc-Lys (acetyl)-AMC was used for HDAC1, HDAC2, HDAC3, HDAC8 and HDAC6 while Boc-Lys (triflouroacetyl)-AMC substrate was used for HDAC4) was added. After incubation at 37 C for 30 min, the mixture was stopped by addition of 100 mL of developer containing trypsin and Trichostatin A (TSA). 20 min later, fluorescence intensity was measured using a microplate reader at excitation and emission wavelengths of 390 and 460 nm, respectively. The inhibition ratios were calculated from the fluorescence intensity readings of tested wells relative to those of control wells, and the IC 50 values were calculated using a regression analysis of the concentration/inhibition data.
In vitro antiproliferative assay
In vitro antiproliferative assays were determined by the MTT (3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl-2H-tetrazolium bromide) method as previously described. 17 All cell lines were maintained in RPMI1640 medium containing 10% FBS at 37 C in a 5% CO 2 humidified incubator. Cells were passaged the day before dosing into a 96-well cell plate, allowed to grow for 12 h, and then treated with different concentrations of compound for 48 h. A 0.5% MTT solution was added to each well. After incubation for another 4 h, formazan formed from MTT was extracted by adding 150 mL of DMSO rocking for 15 min. Absorbance was then determined using an ELISA reader at 570 nm.
In vivo antitumor assay against U937 and HCT116 xenograft
All experiments involving laboratory animals were conducted with the approved of the local ethics committee. For in vivo antitumor efficacy research, 1 Â 10 7 U937 or HCT116 Cells were inoculated subcutaneously in the right flank of male nude mice (5e6 weeks old, SLAC LABORATORY ANIMAL, Shanghai). Ten days after injection, tumors were palpable and mice were randomized into treatment and control groups (6 or 7 mice per group). The treatment groups received compound 9b, MS275 or SAHA by oral administration, and the blank control group received equal volume of PBS solution containing 5% DMSO. During treatment, subcutaneous tumors were measured with vernier caliper every three days, and body weight was monitored regularly. After treatment, mice were sacrificed and dissected to weigh the tumor tissues and to examine the internal organ injury. Tumor growth inhibition (TGI) and relative increment ratio (T/C) were used as the evaluation indicators to reveal the antitumor effects in tumor weight and tumor volume, respectively. Data were analyzed by Student's twotailed t-test. A P level <0.05 was considered statistically significant. TGI ¼ (the mean tumor weight of control group e the mean tumor weight of treated group)/the mean tumor weight of control group.
Tumor volumes (V) were estimated using equation (V ¼ ab 2 /2, where a and b stand for the longest and shortest diameter, respectively). T/C was calculated according to the following formula: T/C ¼ the mean RTV of treated group/the mean RTV of control group.
RTV, namely relative tumor volume ¼ V t /V 0 (V t : the tumor volume measured at the end of treatment; V 0 : the tumor volume measured at the beginning of treatment).
Western blot analysis
HL60 cells were plated at 500,000 cells/mL, 3 mL in flat bottom 6-well plates and allowed to grow for 12 h, and then treated with different concentrations of compounds. 48 h later, cells were harvested, washed by PBS, and lysed with RIPA buffer which was comprised of 50 mM Tris Base, 150 mM NaCl, 5 mM EDTA, 0.1% (v/v) SDS, 0.5% (v/v) Sodium Deoxycholate, and 1% (v/v) Triton-x-100. After lysing, the suspension was ultra-sonicated and centrifuged at 14000 RPM for 15 min at 4 C. The mixture of 75 mL of supernatant and 25 mL of b-mercaptoethanol:LDS solution (15:85) was heated at 90 C for 15 min and normalization according BCA test before loading. Lysates were run on Invitrogen NuPAGE 4e12% BisTris 15 well gels at 170 V for approximately 60 min in MES buffer. Gels were transferred to methylcellulose and ran at 30 V for 3 h. Membranes were incubated at 4 C overnight with 1/1000 primary antibodies, which were diluted in 2.5% (w/v) milk or 5% (w/v) Bovine Serum Albumin. The membrane was washed twice with TBST buffer before incubated with secondary antibodies. Images were acquired using a GE ImageQuant LAS 4000.
